Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | prostaglandin E receptor 1 (subtype EP1), 42kDa | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0082 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0082 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0082 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0082 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0082 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0082 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0082 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0041 | 0 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0082 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0073 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0082 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0082 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0041 | 0 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0051 | 0.2407 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0082 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0073 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0082 | 1 | 0.5 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0082 | 1 | 0.5 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0041 | 0.0151 | 0.0151 |
Brugia malayi | FAD binding domain containing protein | 0.0082 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0082 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0082 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0082 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0082 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0051 | 0.2407 | 0.2407 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0082 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0082 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0082 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0082 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = -7.6 | Displacement of [3H]PGE2 from human recombinant EP1 receptor expressed in CHO cell membrane | ChEMBL. | 17574410 |
IC50 (binding) | = 25 nM | Displacement of [3H]PGE2 from human recombinant EP1 receptor expressed in CHO cell membrane | ChEMBL. | 17574410 |
IC50 (binding) | = 25 nM | Displacement of [3H]PGE2 from human recombinant EP1 receptor expressed in CHO cell membrane | ChEMBL. | 17574410 |
Ki (binding) | = -7.6 | Displacement of [3H]PGE2 from EP1 expressed in CHO cells | ChEMBL. | 17236765 |
Ki (functional) | = -7.45 | Antagonist activity at human EP1 expressed in CHOK1 cells receptor assessed as inhibition of intracellular calcium mobilization by FLIPR assay | ChEMBL. | 17236765 |
Log IC50 (binding) | = 7.6 | Displacement of [3H]PGE2 from human recombinant EP1 receptor expressed in CHO cell membrane | ChEMBL. | 17574410 |
Log Ki (functional) | = 7.45 | Antagonist activity at human EP1 expressed in CHOK1 cells receptor assessed as inhibition of intracellular calcium mobilization by FLIPR assay | ChEMBL. | 17236765 |
Log Ki (binding) | = 7.6 | Displacement of [3H]PGE2 from EP1 expressed in CHO cells | ChEMBL. | 17236765 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.